$CLBT

Cellebrite DI Ltd. (CLBT) announced that its cloud-based digital evidence management platform, Guardian, has achieved a PROTECTED classification level under the Infosec Registered Assessors Program (IRAP) in Australia. This milestone allows Australian government agencies to use Guardian for secure digital evidence collaboration. The assessment was conducted by CyberCX, an Australian Signals Directorate-endorsed IRAP assessor.

Cellebrite DI Ltd (CLBT) announced its subsidiary achieved CMMC Level 2 certification. GF Value™ estimates CLBT is 26.6% undervalued at $12.01 vs. $16.36 intrinsic value. CLBT has a GF Score™ of 87, strong financials, and 11.2% 3-year revenue growth. Insiders sold $5.2M shares, while 5 gurus hold positions.

Cellebrite (CLBT) announced its subsidiary, Cellebrite Federal Solutions (CFSI), achieved CMMC Level 2 cybersecurity certification, a DoW standard for handling Controlled Unclassified Information. CFSI implemented 110 security practices across 14 control families, according to the company. This certification and recent FedRAMP High authorization position CFSI as a trusted partner for federal agencies.

Cellebrite's subsidiary, Cellebrite Federal Solutions (CFSI), achieved CMMC Level 2 certification, implementing 110 security practices. This early certification, verified by a third party, places CFSI among the top 3% of organizations meeting the Department of War standard, supporting its work with U.S. federal agencies.

Cellebrite DI (CLBT) said it launched its rugged C-TEK kit for real-time mobile forensics and expanded its AI Genesis investigation platform to more global public sector and enterprise customers in August 2026. The article cites 2029 forecasts of $787.4M revenue and $122.0M earnings.

Hogan Thomas E. sold 25,299 shares of Cellebrite DI Ltd. (CLBT) at $11.29 ($0.29M total) on 2026-08-25.

Cellebrite DI (CLBT) reported H1 2026 results, announced a CEO transition, and lowered full-year revenue guidance due to expansion plans. Shares are down 20.58% in 30 days and 36.72% YTD, but up 44.93% over 3 years. Analysts debate its valuation, with some citing undervaluation due to subscription growth and others pointing to high P/E ratios.

Cellebrite DI Ltd. (CLBT) is under investigation by Kaplan Fox & Kilsheimer LLP after missing Q2 ARR guidance of $507.8M (vs. $510M-$513M) and cutting full-year guidance by $15M. The company also replaced its CEO, leading to a 29% stock drop. Investors may monitor the investigation's progress.

Cellebrite DI Ltd. (Nasdaq: CLBT) launched the C-TEK, a portable forensics kit for military teams to extract and analyze data from devices in the field. The kit is designed to provide real-time intelligence, crucial for time-sensitive missions. The company is also developing additional field intelligence solutions. According to the company, C-TEK aims to enhance tactical decision-making by making digital data accessible at the point of capture.

Cellebrite (CLBT) launched the C-TEK, a portable forensics kit for military teams to extract and analyze data from devices in the field. The kit aims to provide real-time intelligence, reducing reliance on centralized labs. The company plans to expand its field intelligence solutions with additional tools, including a portable analytics platform and AI capabilities.